|Mr. Dennis M. Lanfear||Chairman, Pres & CEO||1.86M||4.26M||1955|
|Mr. McDavid Stilwell||Chief Financial Officer||756k||N/A||1972|
|Mr. Vladimir Vexler Ph.D.||Chief Scientific Officer||778.28k||843.84k||1958|
|Mr. Bryan J. Mcmichael||Sr. VP of Accounting, Principal Accounting Officer & Corp. Controller||N/A||N/A||1978|
|Mr. Richard L. Hameister||Chief Technical Officer||N/A||N/A||N/A|
|Mr. Christopher W. Slavinsky||Chief Bus. & Legal Officer||N/A||N/A||1973|
|Cheston Turbyfill||VP of Communications||N/A||N/A||N/A|
|Ms. Karen Kotz||Exec. VP of Sales & Strategic Accounts||N/A||N/A||N/A|
|Ms. Rebecca Sunshine||Chief HR Officer||N/A||N/A||1963|
|Mr. Michael Chen||Sr. VP of Commercial Analytics & Trade||N/A||N/A||N/A|
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Coherus BioSciences, Inc.’s ISS governance QualityScore as of 28 January 2023 is 8. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 9.